The attractiveness of the healthcare sector is hard to dispute. Messenger RNA biotech startup Laronde’s $440 million series B funding round and biotech servicer Ten23 Health’s announced investment from 3i Group today are only the latest incarnations of investor interest. Promising new prescription volume data is only likely to make the sector shine further.
To read the entire story, you must be logged in.
Please log in now or register with us.
